NASDAQ: CTXRCitius Pharmaceuticals Inc Stock
$2.21+0.11 (+5.24%)
Updated Jul 3, 2025
CTXR Price
$2.21
Fair Value Price
$0.26
Market Cap
$22.74M
52 Week Low
$0.65
52 Week High
$26.25
P/E
-0.38x
P/B
0.37x
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
$0.00
Earnings
-$42.05M
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Debt to Equity
0.96
Operating Cash Flow
-$24M
Beta
0.87
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A
CTXR Overview
Citius Pharmaceuticals, Inc., a specialty pharmaceutical company, engages in the development and commercialization of critical care products focusing on anti-infective products in adjunct cancer care, prescription products, and mesenchymal stem cell therapy. The company is developing five proprietary products comprising Mino-Lok, an antibiotic lock solution to treat patients with catheter-related bloodstream infections by salvaging the infected catheter; Mino-Wrap, a liquifying gel-based wrap for reduction of tissue expander infections following breast reconstructive surgeries; Halo-Lido, a corticosteroid-lidocaine topical formulation that intends to provide anti-inflammatory and anesthetic relief to persons suffering from hemorrhoids; NoveCite, a mesenchymal stem cell therapy for the treatment of acute respiratory disease syndrome; and I/ONTAK, an engineered IL-2 diphtheria toxin fusion protein for the treatment of patients with persistent or recurrent cutaneous T-cell lymphoma. Citius Pharmaceuticals, Inc. was founded in 2007 and is headquartered in Cranford, New Jersey.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine CTXR's potential to beat the market
FStrong Sell
- Stocks with a Zen Rating of Strong Sell (F) had an average loss of -8.02% per year. Learn More
Zen Rating Component Grades
F
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Biotech
Industry Rating
F
CTXR
Ranked#427 of 468
Ranked#427 of 468
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $7.59 | A | |
| $3.58 | A | |
| $46.15 | A |
Be the first to know about important CTXR news, forecast changes, insider trades & much more!
CTXR News
Overview
Due Diligence Score
–
Industry Average (24)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how CTXR scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
CTXR ($2.21) is overvalued by 756.97% relative to our estimate of its Fair Value price of $0.26 based on Discounted Cash Flow (DCF) modelling
Below Fair Value Valuation
CTXR ($2.21) is not significantly undervalued (756.97%) relative to our estimate of its Fair Value price of $0.26 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
CTXR is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more CTXR due diligence checks available for Premium users.
Valuation
CTXR fair value
Fair Value of CTXR stock based on Discounted Cash Flow (DCF)
Price
$2.21
Fair Value
$0.26
Overvalued by
756.97%
CTXR ($2.21) is overvalued by... subscribe to Premium to read more.
Below Fair Value Valuation
CTXR ($2.21) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
CTXR is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
CTXR price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-0.38x
Industry
-154.26x
Market
30.96x
CTXR price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
0.37x
Industry
4.54x
CTXR is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
CTXR's financial health
Profit margin
Revenue
$0.0
Net Income
-$10.9M
Profit Margin
0%
CTXR's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
Assets to liabilities
Assets
$121.5M
Liabilities
$57.9M
Debt to equity
0.96
CTXR's short-term liabilities ($49.88M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
CTXR's short-term assets ($18.37M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
CTXR's debt has increased relative... subscribe to Premium to read more.
Shrinking Debt Financials
CTXR's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$4.5M
Investing
$0.0
Financing
$3.5M
CTXR's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
CTXR vs Biotech Stocks
Citius Pharmaceuticals Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.